| |
Financial Year 2009 - 2010
Quarter I
(June 2009)
Financial Year 2008 - 2009
Quarter IV
(March 2009)
Quarter III
(December 2008)
Quarter II
(September 2008)
Quarter I
(June 2008)
Financial Year 2007 - 2008
Quarter IV
(March 2008)
Quarter III
(December 2007)
Quarter II
(September 2007)
Quarter I
(June 2007)
Financial Year 2006 - 2007
Quarter IV
(March 2007)
Quarter III
(December 2006)
Quarter II
(September 2006)
Quarter I
(June 2006)
Financial Year 2005 - 2006
Quarter IV
(March 2006)
Quarter III
(December 2005)
Quarter II
(September 2005)
Quarter I
(June 2005)
Financial Year 2004 - 2005
Quarter IV
(March 2005)
Quarter III
(December 2004)
Quarter II
(September 2004)
Quarter I
(June 2004)
Financial Year 2003 - 2004
Quarter IV
(March 2004)
Quarter III
(December 2003)
Quarter II
(September 2003)
Quarter I
(June 2003)
Financial Year 2002 - 2003
Quarter IV
(March 2003)
Quarter III
(December 2002)
Quarter II
(September 2002)
Quarter I
(June 2002)
|
MATRIX LABORATORIES LIMITED
1-1-151/1, IV FLOOR, SAIRAM TOWERS, ALEXANDER ROAD SECUNDERABAD- 500 003
UNAUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER ENDED
30TH SEPTEMBER 2008
| (Rs. in Lakhs) |
| Sl. No |
Particulars |
Quarter ended 30th September |
Half Year ended 30th September |
Year ended
31st March 2008
(Audited) |
| 2008 (Un Audited) |
2007 (Un Audited) |
2008 (Un Audited) |
2007 (Un Audited) |
01.
02.
03.
04.
05.
06.
07.
08.
09.
10.
11.
12.
13.
14.
15.
16.
17.
18.
19.
|
a) Net Sales / Income from
| | Operations
| | - Sales (net)
b) Other Operating Income
| | - Other Income from Operations
| | - Income from Potential
| | | | patent infringement suit
Total
Expenditure
a) (Increase) / Decrease in
| | | | | Stock trade and work
| | | | | | in progress
b) Materials Consumed
c) Purchase of traded goods
d) Employee cost
e)Depreciation
| | & Amortization
f)Other Expenditure
Total Expenditure
Profit from operations
before other income,
interest, exceptional items
and R&D (1-2)
Research and Development
| Expenditure
Interest
Profit from Operations
before Other Income,
Interest & Exceptional
Items (3-4)
Other income
Profit before Interest &
Exceptional Items (5+6)
Interest and Finance Cost
Profit after Interest but
before Exceptional
Items (7-8)
Provision for impairment of
goodwill
Profit / (Loss) before tax
and after exceptional
| item (9-10)
Tax expense
Profit / (Loss) after Tax but
before Minority Interest
and share in Associate
(11-12)
Less : Minority Interest
share of Profit / Loss
Less : Share of Loss
in Associate
Net Profit / (Loss) after
Tax (13-14-15)
Paid-up equity share capital (Face value - Rs.2 each)
Reserves excluding revaluation
reserves
Earning Per Share (Not
annualised) - (Face Value
- Rs.2 each)
On Profit / (Loss) after Tax :
- Before Exceptional Item
| | - Basic ( Rs )
| | - Diluted ( Rs )
- After Exceptional Item
| | - Basic ( Rs )
| | - Diluted ( Rs )
|
51439
133
677
52249
(6261)
23555
6948
5573
1632
9488
40935
11314
5359
5955
929
6884
3946
2938
-
2938
1872
1066
(49)
(128)
889
3092
-
0.58
0.58
0.58
0.58
|
37641
220
677
38538
(3923)
16826
6490
4102
1493
7961
32949
5589
3475
2114
432
2546
2351
195
-
195
1253
(1058)
121
(55)
(992)
3090
-
(0.64)
(0.64)
(0.64)
(0.64)
|
104760
223
1346
106329
(5421)
39682
17578
11541
3268
18544
85192
21137
10872
10265
1583
11848
7003
4845
-
4845
3386
1459
(70)
(128)
1261
3092
-
0.82
0.82
0.82
0.82
|
82343
319
1345
84007
327
28298
15414
8665
2986
15118
70808
13199
6395
6804
1385
8189
4431
3758
-
3758
2328
1430
321
(55)
1696
3090
-
1.10
1.10
1.10
1.10
|
172807
661
2691
176159
(8168)
65967
32201
18825
6055
31989
146869
29290
14233
15057
2447
17504
9604
7900
48712
(40812)
5297
(46109)
419
(3)
(45693)
3092
65388
1.96
1.95
(29.59)
(29.59)
|
Segment Information:
| | | | Net Segment Revenue:
| | | | | | -Pharmaceuticals
| | | | | | -Medical Supplies
| | | | Total
| | | | Segment Results :
| | | | Profit before tax and interest
| | | | from each segment
| | | | | | -Pharmaceuticals
| | | | | | -Medical Supplies
| | | | Total
| | | | Less: Interest & Finance cost
| | | | Total Profit before tax and
| | | | Exceptional Items
| | | | Capital Employed :
| | | | | | -Pharmaceuticals
| | | | | | -Medical Supplies
| | | | | | -Unallocated
| | | | Total
|
46817
4622
51439
6392
492
6884
(3946)
2938
179772
5801
86513
272086
|
34243
3398
37641
2490
56
2546
(2351)
195
132395
3782
117147
253324
|
95199
9561
104760
11057
791
11848
(7003)
4845
179772
5801
86513
272086
|
75011
7332
82343
7911
278
8189
(4431)
3758
132395
3782
117147
253324
|
157067
15740
172807
16933
571
17504
(9604)
7900
156740
4825
79771
241336
|
|
| Notes : |
The above results were subjected to a limited review by the Auditors, reviewed by the Audit Committee and approved at the meeting of the Board of Directors of the Company held on 29th October 2008.
The figures for the previous year / period have been / regrouped wherever necessary to conform to current period's presentation.
On 9th October, 2008, Matrix Laboratories Limited, India (Matrix) and Aspen Pharmacare Holdings Limited, South Africa (Aspen), executed agreements pursuant to which, generally speaking, Matrix Laboratories BV, Netherlands, a wholly owned subsidiary of Matrix would divest its stake in Fine Chemicals Corporation (Proprietary) Limited, to Aspen, and additionally Aspen would divest its stake in Astrix Laboratories Limited to Matrix. The divestments are subject to receipt of applicable regulatory approvals.
|
| |
For and on behalf of the Board
|
| | | Place : Secunderabad
| | | Date : 29th October 2008 |
Jagdish Dore
Managing Director & Chief Executive Officer
|
|
UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED
30TH SEPTEMBER 2008
| (Rs. in Lakhs ) |
| Sl. No |
Particulars |
Quarter ended 30th September |
Half year ended 30th september |
Year ended
31st March 2008
(Audited) |
| 2008 (Un Audited) |
2007 (Un Audited) |
2008 (Un Audited) |
2007 (Un Audited) |
01.
02.
03.
04.
05.
06.
07.
08.
09.
10.
11.
12.
13.
14.
15.
16.
17.
| Net Sales / Income from Operation
| -Exports
| -Domestic
b) Other Operating Income
| -Other Income from Operations
| -Income from Potential patent
| | | infringement suit
Total
Expenditure
a) Increase in Stock in trade and
work in progress
b) Materials Consumed
c) Purchase of traded goods
d)Employee cost
e)Depreciation & Amortization
| (excluding R & D)
f) Other Expenditure
g) Total
Profit from Operations
before Other Income,
Interest, Exceptional Items
and R&D (1-2)
Research and Development
Expenditure(including
depreciation)
Profit from Operations
before Other Income,
Interest & Exceptional
Items (3-4)
Other Income
Profit before Interest
& Exceptional Items (5+6)
Interest and Finance Cost
Profit after Interest but
before Exceptional
Items (7-8)
Provision for diminution in
the value of investment
in subsidiary
Profit/(Loss) before tax
and after exceptional
item (9-10)
Tax expense
Net Profit/(Loss) after
tax (11-12)
Paid-up equity share capital
(Face value - Rs.2/- each)
Reserves excluding
revaluation reserves
Earning Per Share (EPS) Not
annualised) On Profit / (Loss)
after Tax :
Before Exceptional Item
| - Basic
| - Diluted
After Exceptional Item
| - Basic
| - Diluted
Public Shareholding
| - Number of shares
| - Percentage of shareholding
|
28562
3921
265
677
33425
(6804)
20754
93
2152
865
4851
21911
11514
4345
7169
643
7812
1351
6461
-
6461
1495
4966
3092
-
3.22
3.21
3.22
3.21
36903471
23.87%
|
11798
8407
440
677
21322
(1735)
12063
8
1595
714
3888
16533
4789
2413
2376
414
2790
559
2231
-
2231
867
1364
3090
-
0.88
0.88
0.88
0.88
36782911
23.81%
|
52294
11895
445
1346
65980
(6093)
34743
641
4583
1699
9338
44911
21069
8968
12101
1101
13202
2396
10806
-
10806
2603
8203
3092
-
5.31
5.30
5.31
5.30
36903471
23.87%
|
25247
15568
638
1346
42799
(1322)
22168
13
3447
1459
7292
33057
9742
4512
5230
1161
6391
1036
5355
-
5355
1412
3943
3090
-
2.56
2.54
2.56
2.54
36782911
23.81%
|
62066
31797
1322
2691
97876
(7258)
53367
354
7038
2954
15991
72446
25430
10641
14789
2018
16807
2677
14130
40118
(25988)
3848
(29836)
3092
64899
6.66
6.64
(19.32)
(19.32)
36876696
23.85%
|
|
| Notes : |
- The above results were subjected to a limited review by the auditors, reviewed by the Audit Committee and approved at the meeting of the Board of Directors of the Company held on 29th October 2008.
- The activities of the Company relate to only one business segment i.e.Pharmaceuticals.
- Tax expense includes Current tax Rs.732 lakhs (Quarter ended 30th September 2007 Rs.230 lakhs), Deferred Tax Rs.762 lakhs (Quarter ended 30th September 2007 Rs.635 lakhs) and Fringe benefit tax Rs.33 lakhs (Quarter ended 30th September 2007 Rs.70 lakhs) and is net of MAT credit available of Rs.32 lakhs (Quarter ended 30th September 2007 Rs.68 lakhs).
- The figures for the previous year / period have been rearranged/regrouped wherever necessary to conform to current period's presentation.
- Summary of Investor Complaints :
Opening : Nil, Received during the quarter : 2, Resolved : 2, Closing : Nil.
- On 9th October, 2008, Matrix Laboratories Limited, India (Matrix) and Aspen Pharmacare Holdings Limited, South Africa (Aspen), executed agreements pursuant to which, generally speaking, Matrix Laboratories BV, Netherlands, a wholly owned subsidiary of Matrix would divest its stake in Fine Chemicals Corporation (Proprietary) Limited, to Aspen, and additionally Aspen would divest its stake in Astrix Laboratories Limited to Matrix. The divestments are subject to the receipt of applicable regulatory approvals.
|
| |
For and on behalf of the Board
|
| | | Place : Secunderabad
| | | Date : 29th October 2008 |
Jagdish Dore
Managing Director & Chief Executive Officer
|
|
|
